Lipidomic biomarkers associated with and predictive of rapid progression of renal disease in type 2 diabetes

被引：0
|
作者：
Colombo, M. [1 ]
Looker, H. C. [2 ]
Farran, B. [2 ]
Agakov, F. [3 ]
Sanders, P. E. [4 ]
Kuo, M. S. [4 ]
Homas, M. K. [4 ]
McKeigue, P. [1 ]
Colhoun, H. M. [2 ]
机构：
[1] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland
[2] Univ Dundee, Dundee DD1 4HN, Scotland
[3] Pharmatics Ltd, Edinburgh, Midlothian, Scotland
[4] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
11
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [41] Lack of association between anemia and renal disease progression in Chinese patients with type 2 diabetes
    Gu, Liubao
    Lou, Qinglin
    Wu, Haidi
    Ouyang, Xiaojun
    Bian, Rongwen
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (01) : 42 - 47
  • [42] Lipidome as a predictive tool in progression to type 2 diabetes in Finnish men
    Suvitaival, Tommi
    Bondia-Pons, Isabel
    Yetukuri, Laxman
    Poho, Paivi
    Nolan, John J.
    Hyotylainen, Tuulia
    Kuusisto, Johanna
    Oresic, Matej
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 78 : 1 - 12
  • [43] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Wanner, Christoph
    Inzucchi, Silvio E.
    Lachin, John M.
    Fitchett, David
    von Eynatten, Maximilian
    Mattheus, Michaela
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Zinman, Bernard
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (04): : 323 - 334
  • [44] Clinical predictors of disease progression in type 2 diabetes
    Pani, Lydie N.
    Grant, Richard W.
    Nathan, David M.
    DIABETES, 2007, 56 : A269 - A269
  • [45] Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
    Pareek, Anil
    Chandurkar, Nitin
    Naidu, Kumar
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1800 - 1800
  • [46] Predictive biomarkers for chronic kidney disease in diabetes
    Zuraeva, Z.
    Mikhaleva, O.
    Vikulova, O.
    Ilyin, A.
    Shamkhalova, M.
    Shestakova, M.
    Dedov, I.
    DIABETOLOGIA, 2016, 59 : S493 - S493
  • [47] Lipidomic studies revealing serological markers associated with the occurrence of retinopathy in type 2 diabetes
    He, Mingqian
    Hou, Guixue
    Liu, Mengmeng
    Peng, Zhaoyi
    Guo, Hui
    Wang, Yue
    Sui, Jing
    Liu, Hui
    Yin, Xiaoming
    Zhang, Meng
    Chen, Ziyi
    Rensen, Patrick C. N.
    Lin, Liang
    Wang, Yanan
    Shi, Bingyin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [48] Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
    Zhu, Weiwei
    Liu, Chunquan
    Tan, Chunting
    Zhang, Jie
    HELIYON, 2024, 10 (01)
  • [49] Rapid MS disease progression is histopathologically associated with a new lesions type
    Kuhlmann, T.
    Klotz, L.
    Smolders, J.
    Huitinga, I.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 956 - 956
  • [50] The decorin gene 179 allelic variant is associated with a slower progression of renal disease in patients with type 1 diabetes
    De Cosmo, S
    Tassi, V
    Thomas, S
    Piras, GP
    Trevisan, R
    Perin, PC
    Bacci, S
    Zucaro, L
    Cisternino, C
    Trischitta, V
    Viberti, GC
    NEPHRON, 2002, 92 (01) : 72 - 76
12345